Should access to GLP-1 weight-loss drugs be publicly reimbursed?
14 votes|10 arguments|0 source
36%5
·
Patients regain most of the weight when they stop the drug, implying lifelong prescriptions — fiscally that is unmanageable. @@no_2
Safety surveillance of mRNA COVID-19 vaccines: 3-year follow-up
Research Paper·nejm.org
Pooled safety data from national registries covering ~600 million doses across Europe, North America and Israel.
Added by @ada
GLP-1 agonists: efficacy, cost-effectiveness, and equity
Article·bmj.com
Systematic review of semaglutide and tirzepatide trials and a cost-effectiveness model for public reimbursement.
Added by @lin
WHO priority pathogens list and pandemic preparedness
Report·who.int
Updated assessment of viral families with pandemic potential, including hantaviruses, coronaviruses and arenaviruses.
Added by @tomas
Publicly funded trials of repurposed drugs: the case for state action
Article·thelancet.com
Why off-patent molecules with oncology signals stall, and what public trial infrastructure could change.
Added by @priya